Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?

Casey DL, Pitter KL, Kushner BH, Cheung NV, Modak S, LaQuaglia MP, Wolden SL.

Int J Radiat Oncol Biol Phys. 2018 Jan 9. pii: S0360-3016(18)30008-7. doi: 10.1016/j.ijrobp.2018.01.008. [Epub ahead of print]

PMID:
29439882
2.

MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

Kushner BH, LaQuaglia MP, Modak S, Wolden SL, Basu EM, Roberts SS, Kramer K, Yataghene K, Cheung IY, Cheung NV.

Oncotarget. 2017 Aug 24;8(56):95293-95302. doi: 10.18632/oncotarget.20513. eCollection 2017 Nov 10.

3.

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV.

Oncoimmunology. 2017 Jul 31;6(11):e1358331. doi: 10.1080/2162402X.2017.1358331. eCollection 2017.

PMID:
29147617
4.

Targeting Intracellular Antigens with pMHC-Binding Antibodies: A Phage Display Approach.

Wu Z, Santich BH, Liu H, Liu C, Cheung NV.

Methods Mol Biol. 2018;1701:255-269. doi: 10.1007/978-1-4939-7447-4_13.

PMID:
29116509
5.

Erratum to 'Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies' [Cancer Treat. Rev. 58C (2017) 22-33].

Park JA, Cheung NV.

Cancer Treat Rev. 2017 Nov;60:158. doi: 10.1016/j.ctrv.2017.09.007. Epub 2017 Oct 21. No abstract available.

PMID:
29033261
6.

A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma.

Kramer K, Pandit-Taskar N, Humm JL, Zanzonico PB, Haque S, Dunkel IJ, Wolden SL, Donzelli M, Goldman DA, Lewis JS, Lyashchenko SK, Khakoo Y, Carrasquillo JA, Souweidane MM, Greenfield JP, Lyden D, De Braganca KD, Gilheeney SW, Larson SM, Cheung NV.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26754. Epub 2017 Sep 22.

PMID:
28940863
7.

T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

Wu Z, Cheung NV.

Pharmacol Ther. 2018 Feb;182:161-175. doi: 10.1016/j.pharmthera.2017.08.005. Epub 2017 Aug 20. Review.

PMID:
28834699
8.

Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.

Cheal SM, Fung EK, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Wittrup KD, Cheung NV, Larson SM.

J Nucl Med. 2017 Nov;58(11):1735-1742. doi: 10.2967/jnumed.117.193250. Epub 2017 Jul 13.

PMID:
28705917
9.

Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Park JA, Cheung NV.

Cancer Treat Rev. 2017 Jul;58:22-33. doi: 10.1016/j.ctrv.2017.05.006. Epub 2017 Jun 1. Review. Erratum in: Cancer Treat Rev. 2017 Nov;60:158.

PMID:
28622628
10.

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.

Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, Trippett TM, Gilheeney SW, Khakoo Y, Lyden DC, De Braganca KC, Kolesar JM, Huse JT, Kramer K, Cheung NV, Dunkel IJ.

PLoS One. 2017 Jun 5;12(6):e0178593. doi: 10.1371/journal.pone.0178593. eCollection 2017.

11.

Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies.

Hoseini SS, Cheung NV.

Cancer Lett. 2017 Jul 28;399:44-52. doi: 10.1016/j.canlet.2017.04.013. Epub 2017 Apr 17. Review.

PMID:
28428075
12.

Temporal stability and molecular persistence of the bone marrow plasma cell antibody repertoire.

Wu GC, Cheung NV, Georgiou G, Marcotte EM, Ippolito GC.

Nat Commun. 2016 Dec 21;7:13838. doi: 10.1038/ncomms13838.

13.

A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

Kushner BH, Cheung NV, Modak S, Becher OJ, Basu EM, Roberts SS, Kramer K, Dunkel IJ.

Int J Cancer. 2017 Jan 15;140(2):480-484. doi: 10.1002/ijc.30440. Epub 2016 Sep 30.

14.

Antibody induced pain in children: An opportunity to study pain mechanism, IgG design and analgesics.

Cheung NV.

Pediatr Blood Cancer. 2015 Feb;62(2):186-187. doi: 10.1002/pbc.25320. Epub 2014 Nov 8. No abstract available.

PMID:
25382406
15.

Local control with multimodality therapy for stage 4 neuroblastoma.

Wolden SL, Gollamudi SV, Kushner BH, LaQuaglia M, Kramer K, Rosen N, Abramson S, Cheung NV.

Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):969-74.

PMID:
10705019
16.

Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial.

Grant SC, Kostakoglu L, Kris MG, Yeh SD, Larson SM, Finn RD, Oettgen HF, Cheung NV.

Eur J Nucl Med. 1996 Feb;23(2):145-9.

PMID:
8925848
17.

Reassessment of patient response to monoclonal antibody 3F8.

Cheung NV, Lazarus H, Miraldi FD, Berger NA, Abramowsky CR, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF.

J Clin Oncol. 1992 Apr;10(4):671-2. No abstract available.

PMID:
1548529
19.

A quantitative enzyme-linked immunosorbent assay for honeybee venom-specific immunoglobulin G.

Reid MJ, Kwasnicki JM, Cheung NV.

J Allergy Clin Immunol. 1982 Sep;70(3):191-8.

PMID:
6179974

Supplemental Content

Loading ...
Support Center